AstraZeneca (AZN) ends its license agreement with Abbott Laboratories (ABT) to develop Certriad,...

|About: Abbott Laboratories (ABT)|By:, SA News Editor

AstraZeneca (AZN) ends its license agreement with Abbott Laboratories (ABT) to develop Certriad, prompted by an FDA decision in March 2010 which caused a regulatory delay in the drug's commercialization. The firms felt the licensing agreement was "no longer commercially attractive."